What is HC Wainwright’s Estimate for FBIO Q4 Earnings?

Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) – Equities researchers at HC Wainwright issued their Q4 2026 earnings per share estimates for shares of Fortress Biotech in a research note issued to investors on Tuesday, November 17th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter. The consensus estimate for Fortress Biotech’s current full-year earnings is $2.66 per share.

FBIO has been the topic of a number of other reports. Wall Street Zen downgraded Fortress Biotech from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings cut Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.00.

View Our Latest Analysis on FBIO

Fortress Biotech Stock Performance

Shares of NASDAQ:FBIO opened at $1.78 on Wednesday. The firm has a market capitalization of $60.16 million, a PE ratio of 0.78 and a beta of 1.27. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.93 and a quick ratio of 3.83. The business has a 50-day moving average of $2.07 and a two-hundred day moving average of $2.69. Fortress Biotech has a 12 month low of $1.64 and a 12 month high of $4.53.

Fortress Biotech (NASDAQ:FBIO – Get Free Report) last issued its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.04. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. The firm had revenue of $19.16 million for the quarter, compared to analysts’ expectations of $21.57 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in shares of Fortress Biotech during the third quarter worth about $462,000. Renaissance Technologies LLC boosted its position in shares of Fortress Biotech by 22.8% in the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18,490 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Fortress Biotech in the second quarter valued at about $47,000. 96.51% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Fortress Biotech news, CFO David Jin purchased 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 18th. The stock was purchased at an average cost of $1.91 per share, with a total value of $47,750.00. Following the transaction, the chief financial officer owned 1,692,761 shares in the company, valued at approximately $3,233,173.51. This trade represents a 1.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Lindsay A. Md Rosenwald purchased 64,491 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The shares were acquired at an average cost of $1.80 per share, with a total value of $116,083.80. Following the completion of the transaction, the chief executive officer owned 4,651,332 shares in the company, valued at $8,372,397.60. This trade represents a 1.41% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 184,328 shares of company stock worth $340,398. Insiders own 28.50% of the company’s stock.

Key Fortress Biotech News

Here’s some of the latest news about FBIO:

  • Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
  • Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Read More

Earnings History and Estimates for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.